Variegation of retroviral vector gene expression in myeloid cells

[1]  J. Sambrook,et al.  Molecular Cloning: A Laboratory Manual , 2001 .

[2]  A. Thrasher,et al.  High efficiency gene transfer to human hematopoietic SCID-repopulating cells under serum-free conditions. , 1998, Blood.

[3]  D. Kohn,et al.  High-resolution analysis of cytosine methylation in the 5ĺong terminal repeat of retroviral vectors. , 1998, Human gene therapy.

[4]  W. Ostertag,et al.  FMEV vectors: both retroviral long terminal repeat and leader are important for high expression in transduced hematopoietic cells , 1998, Gene Therapy.

[5]  P. Robbins,et al.  The selectable marker neo gene down-regulates gene expression from retroviral vectors containing an internal ribosome entry site , 1998, Gene Therapy.

[6]  D. Kohn,et al.  Consistent, persistent expression from modified retroviral vectors in murine hematopoietic stem cells. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[7]  A. Ganser,et al.  Correction of respiratory burst activity in X-linked chronic granulomatous cells to therapeutically relevant levels after gene transfer into bone marrow CD34+ cells. , 1998, Human gene therapy.

[8]  K. Weinberg,et al.  T lymphocytes with a normal ADA gene accumulate after transplantation of transduced autologous umbilical cord blood CD34+ cells in ADA-deficient SCID neonates , 1998, Nature Medicine.

[9]  J. Strouboulis,et al.  Methylated DNA and MeCP2 recruit histone deacetylase to repress transcription , 1998, Nature Genetics.

[10]  Colin A. Johnson,et al.  Transcriptional repression by the methyl-CpG-binding protein MeCP2 involves a histone deacetylase complex , 1998, Nature.

[11]  Johann Meyer,et al.  Host cis-Mediated Extinction of a Retrovirus Permissive for Expression in Embryonal Stem Cells during Differentiation , 1998, Journal of Virology.

[12]  L. Taichman,et al.  Repression of retrovirus-mediated transgene expression by interferons: implications for gene therapy , 1997, Journal of virology.

[13]  D. Kohn,et al.  Increased probability of expression from modified retroviral vectors in embryonal stem cells and embryonal carcinoma cells , 1997, Journal of virology.

[14]  S. Holland,et al.  Prolonged production of NADPH oxidase-corrected granulocytes after gene therapy of chronic granulomatous disease. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[15]  C. Eaves,et al.  Sustained high-level reconstitution of the hematopoietic system by preselected hematopoietic cells expressing a transduced cell-surface antigen. , 1997, Human gene therapy.

[16]  David A. Williams,et al.  Identification of primitive human hematopoietic cells capable of repopulating NOD/SCID mouse bone marrow: Implications for gene therapy , 1996, Nature Medicine.

[17]  D. Roos.  X-CGDbase: a database of X-CGD-causing mutations. , 1996, Immunology today.

[18]  M. Dinauer,et al.  High-level reconstitution of respiratory burst activity in a human X-linked chronic granulomatous disease (X-CGD) cell line and correction of murine X-CGD bone marrow cells by retroviral-mediated gene transfer of human gp91phox. , 1996, Blood.

[19]  P. Robbins,et al.  Analysis of the relative level of gene expression from different retroviral vectors used for gene therapy. , 1996, Gene therapy.

[20]  L. Zentilin,et al.  Rapid retrovirus titration using competitive polymerase chain reaction. , 1996, Gene therapy.

[21]  L. Zentilin,et al.  Functional reconstitution of oxidase activity in X-linked chronic granulomatous disease by retrovirus-mediated gene transfer. , 1996, Experimental cell research.

[22]  Barranger Ja.  Hematopoietic stem cell gene transfer. , 1996 .

[23]  D. Scalzo,et al.  Transcriptional enhancers act in cis to suppress position-effect variegation. , 1996, Genes & development.

[24]  S. Hegewisch-Becker,et al.  Novel retroviral vectors for efficient expression of the multidrug resistance (mdr-1) gene in early hematopoietic cells , 1995, Journal of virology.

[25]  M. Groudine,et al.  Enhancers increase the probability but not the level of gene expression. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[26]  A. Nienhuis,et al.  Retrovirally marked CD34-enriched peripheral blood and bone marrow cells contribute to long-term engraftment after autologous transplantation. , 1995, Blood.

[27]  D. Kohn.  The current status of gene therapy using hematopoietic stem cells. , 1995, Current opinion in pediatrics.

[28]  M. Dinauer,et al.  Retrovirus-mediated reconstitution of respiratory burst activity in X-linked chronic granulomatous disease cells. , 1994, Blood.

[29]  R. Vile,et al.  A comparison of the properties of different retroviral vectors containing the murine tyrosinase promoter to achieve transcriptionally targeted expression of the HSVtk or IL-2 genes. , 1994, Gene therapy.

[30]  L. Zentilin,et al.  Fine mapping of a replication origin of human DNA. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[31]  D. Roos.  The Genetic Basis of Chronic Granulomatous Disease , 1994, Immunological reviews.

[32]  D. Kohn,et al.  Lack of expression from a retroviral vector after transduction of murine hematopoietic stem cells is associated with methylation in vivo. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[33]  T. Wright,et al.  A unique palindromic element mediates gamma interferon induction of mig gene expression , 1994, Molecular and cellular biology.

[34]  S. Chanock,et al.  Gene targeting of X chromosome-linked chronic granulomatous disease locus in a human myeloid leukemia cell line and rescue by expression of recombinant gp91phox. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[35]  S. Orkin,et al.  Long-term in vivo expression of a murine adenosine deaminase gene in rhesus monkey hematopoietic cells of multiple lineages after retroviral mediated gene transfer into CD34+ bone marrow cells. , 1993, Blood.

[36]  L. Zentilin,et al.  A novel procedure for quantitative polymerase chain reaction by coamplification of competitive templates. , 1992, Gene.

[37]  C. Porter,et al.  Superoxide production by normal and chronic granulomatous disease (CGD) patient-derived EBV-transformed B cell lines measured by chemiluminescence-based assays. , 1992, Journal of immunological methods.

[38]  Adrian Bird,et al.  The essentials of DNA methylation , 1992, Cell.

[39]  M. Grez,et al.  A single point mutation activates the Moloney murine leukemia virus long terminal repeat in embryonal stem cells , 1991, Journal of virology.

[40]  M. Hatzoglou,et al.  Hormonal control of interacting promoters introduced into cells by retroviruses. , 1991, The Journal of biological chemistry.

[41]  E. Barklis,et al.  A stem cell-specific silencer in the primer-binding site of a retrovirus , 1991, Molecular and cellular biology.

[42]  M. Grez,et al.  Determinants of retrovirus gene expression in embryonal carcinoma cells , 1991, Journal of virology.

[43]  H. Land,et al.  Advanced mammalian gene transfer: high titre retroviral vectors with multiple drug selection markers and a complementary helper-free packaging cell line. , 1990, Nucleic acids research.

[44]  B. Seliger,et al.  Distinct mechanisms of interferon‐gamma and tumor necrosis factor‐alpha action in oncogene‐transformed mouse fibroblasts , 1988, Journal of cellular biochemistry.

[45]  D. Bowtell,et al.  Comparison of expression in hemopoietic cells by retroviral vectors carrying two genes , 1988, Journal of virology.

[46]  M. Lilly,et al.  Characterization of a new human diploid myeloid leukemia cell line (PLB-985) with granulocytic and monocytic differentiating capacity. , 1987, Blood.

[47]  M. Emerman,et al.  Quantitative analysis of gene suppression in integrated retrovirus vectors , 1986, Molecular and cellular biology.

[48]  M. Emerman,et al.  Genes with promoters in retrovirus vectors can be independently suppressed by an epigenetic mechanism , 1984, Cell.

[49]  O. Niwa,et al.  Independent mechanisms involved in suppression of the moloney leukemia virus genome during differentiation of murine teratocarcinoma cells , 1983, Cell.

[50]  Michael C. Wilson,et al.  Delayed de novo methylation in teratocarcinoma suggests additional tissue-specific mechanisms for controlling gene expression , 1983, Nature.

[51]  D. Metcalf.  In-vitro cloning techniques for hemopoietic cells: clinical applications. , 1977, Annals of internal medicine.

[52]  C. Dunbar,et al.  Gene transfer to hematopoietic stem cells: implications for gene therapy of human disease. , 1996, Annual review of medicine.

[53]  John I. Gallin,et al.  A controlled trial of interferon gamma to prevent infection in chronic granulomatous disease. The International Chronic Granulomatous Disease Cooperative Study Group. , 1991, The New England journal of medicine.

[54]  E. Linney,et al.  Non-function of a Moloney murine leukaemia virus regulatory sequence in F9 embryonal carcinoma cells , 1984, Nature.